«It is no longer reasonable to believe that oral formulations of HCQ and CQ may be effective in treating COVID-19.»
The Food and Drug Administration (FDA) is rescinding its Emergency Use Authorization (EUA) for the drugs hydroxychloroquine and chloroquine as a treatment for coronavirus. President Donald Trump has touted hydroxychloroquine as a potential treatment for the coronavirus.
FDA Chief Scientist Denise Hinton wrote in a letter on Monday, “We now believe that the suggested dosing regimens for [chloroquine and hydroxychloroquine] as detailed in the Fact Sheets are unlikely to produce an antiviral effect.”
Hinton said, “Recent data from a large randomized controlled trial showed no evidence of benefit for mortality or other outcomes such as hospital length of stay or need for mechanical ventilation of [hydrozycholoroquine] treatment in hospitalized patients with COVID19.”
“FDA has concluded that, based on this new information and other information discussed in the attached memorandum, it is no longer reasonable to believe that oral formulations of HCQ and CQ may be effective in treating COVID-19,” Hinton added.
